Clinical trials: Schizo-affective Disorder
Schizophrenia, Schizoaffective Disorder
Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia
This study will determine the comparative effectiveness of two systems designed to improve medication adherence in people with schizophrenia.
- Trial name
- NCT00406718
- Testing
- Med-eMonitor, PharmCAT, Treatment as Usual
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia, Schizoaffective Disorder
Kuvan in People With Schizophrenia and Schizoaffective Disorder
Rater blinded trial of six weeks of Kuvan vs. multivitamin in 60 outpatients with schizophrenia or schizoaffective disorder. The aims are to evaluate an anticipated clinical response to Kuvan treatment including negative symptom…
- Trial name
- NCT01706965
- Testing
- Kuvan, Multivitamin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
The purpose of this study is to examine the efficacy of quetiapine (Seroquel) in reducing substance use in persons diagnosed with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse
- Trial name
- NCT00156715
- Testing
- Quetiapine
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Schizoaffective Disorder
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of risperidone long-acting injection (LAI) versus oral antipsychotics in participants with recent onset psychosis (abnormal thinking and/or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT00246259
- Testing
- Risperidone long-acting injection (LAI), Oral Antipsychotic
- Where
- 11 sites in Canada
- Volunteers
- 77 people
- Sponsor
- Janssen-Ortho Inc., Canada
Schizophrenia, Schizoaffective Disorder
Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
Schizophrenia is marked by problems in attention, memory and problem solving. These deficits predict long-term functional outcome such as the ability to live independently and maintain employment, but they are not ameliorated by…
- Trial name
- NCT02069392
- Testing
- Cognitive remediation training, Nicotine polacrilex lozenge
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Sodium Nitroprusside in Early Course Schizophrenia
Peripheral inflammation and microvascular dysfunction are central to the pathophysiology of schizophrenia (SZ). Retinal imaging allows for the accurate quantitative assessment of the condition of retinal microvessels, and early…
- Trial name
- NCT04986072
- Testing
- Sodium Nitroprusside, 5% Dextrose solution
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia, Schizoaffective Disorder
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
Treatment of schizophrenia currently includes antipsychotic medications and cognitive therapies which improve some symptoms, but do not sufficiently restore cognitive functioning or reduce psychosocial disability.
- Trial name
- NCT04857983
- Testing
- Memantine
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
Optimizing Response in Psychosis Study
The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
- Trial name
- ORP (NCT00314327)
- Testing
- long-acting injectable risperidone
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.
- Trial name
- NCT06319170
- Testing
- Olanzapine Extended Release, Olanzapine Immediate Release
- Where
- 5 sites in United States
- Volunteers
- 106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia, Schizo Affective Disorder
Examining a Digital Health Approach for Advancing Schizophrenia Illness Self-management and Provider Engagement
The effective treatment of schizophrenia is very challenging due to a number of factors. These include issues such as poor engagement with treatment plans and care providers, limited contacts with providers due to under-resourced…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Psychotic Disorders
- Trial name
- NCT04602741
- Testing
- A4i Intervention
- Where
- Canada
- Volunteers
- 91 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia
The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the administration of a probiotic supplement when used in addition to standard antipsychotic medications.
- Trial name
- NCT01242371
- Testing
- Probiotic Supplement
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Sheppard Pratt Health System
Schizophrenia, Schizo Affective Disorder
Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Healthy
- Trial name
- NCT03860597
- Testing
- Memantine
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Schizophrenia, Schizophreniform Disorders
Horyzons: Implementation and Integration in Clinical Practice
The primary aim of this trial is evaluating the barriers and enablers of implementing a digital intervention with both therapeutic content and social networking, Horyzons, as part of clinical care in first episode psychosis (FEP)…
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Unspecified or Other Psychotic Disorders
- Trial name
- NCT06002958
- Testing
- Horyzons USA
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)
A trial to compare if one 15 mg under the tongue tablet is equal to three 5 mg under the tongue tablets of Org 5222 (asenapine) in subjects with schizophrenia or schizoaffective disorder delivered.
- Trial name
- NCT01101464
- Testing
- Asenapine 3x5mg followed by 1x15mg, Asenapine 1x15mg followed by 3x5mg
- Volunteers
- 8 people
- Sponsor
- Organon and Co
Schizophrenia, Schizoaffective Disorder
Oxytocin and CBSST for People With Schizophrenia
A significant proportion of people with schizophrenia are characterized by impaired ability to socially engage with others, which may reflect social aversion secondary to defeatist beliefs; decreased motivation for social…
- Trial name
- NCT01752712
- Testing
- CBSST + Oxytocin
- Where
- 2 sites in United States
- Volunteers
- 83 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
Primary Objective: To test the effect of pramlintide on body weight in clozapine- and olanzapine-induced weight gain in persons with schizophrenia who are currently taking either drug; measures of the metabolic syndrome will be…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
- Trial name
- NCT00690235
- Testing
- Pramlintide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Texas Southwestern Medical Center
Bipolar Disorder, Schizophrenia
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
- Conditions
- Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder
- Trial name
- NCT06041646
- Testing
- Sublingual film containing Igalmi
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- BioXcel Therapeutics Inc
Major Depression, Bipolar Depression
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat problems with thinking and memory caused by electroconvulsive therapy (ECT).
- Conditions
- Major Depression, Bipolar Depression, Schizoaffective Disorder
- Trial name
- Galantamine (NCT00566735)
- Testing
- Razadyne
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizophreniform Disorder
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
The purpose of this study is to evaluate the efficacy and safety of long acting injectable microspheres of risperidone in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT01855074
- Testing
- Risperidone
- Volunteers
- 80 people
- Sponsor
- Janssen-Cilag Ltd.
Schizophrenia, Medication Nonadherence
Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
The proposed, three phase project will refine and test a first-ever care approach in SSA that combines LAI with a behavioral program specifically intended to promote medication adherence in chronic psychotic disorders (CPDs).
- Conditions
- Schizophrenia, Medication Nonadherence, Schizo Affective Disorder
- Trial name
- CAPACITY (NCT04327843)
- Testing
- Customized Adherence Enhancement, Haloperidol Decanoate
- Where
- Tanzania
- Volunteers
- 22 people
- Sponsor
- Case Western Reserve University